Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $240.00

Krystal Biotech (NASDAQ:KRYS - Get Free Report) had its price objective boosted by equities research analysts at HC Wainwright from $221.00 to $240.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price would indicate a potential upside of 43.41% from the company's previous close.

A number of other equities analysts have also recently issued reports on KRYS. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup lifted their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price on the stock. Finally, Chardan Capital upped their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Krystal Biotech presently has an average rating of "Buy" and an average target price of $222.71.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded down $0.71 on Monday, reaching $167.35. 57,057 shares of the company's stock were exchanged, compared to its average volume of 295,193. The firm's 50-day moving average is $176.37 and its two-hundred day moving average is $171.56. The company has a market capitalization of $4.84 billion, a P/E ratio of 55.97 and a beta of 0.75. Krystal Biotech has a 52 week low of $141.72 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same period in the previous year, the firm posted $0.30 earnings per share. The business's revenue was up 116.4% compared to the same quarter last year. On average, analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company's stock.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently made changes to their positions in KRYS. Norges Bank bought a new position in Krystal Biotech during the 4th quarter worth approximately $34,391,000. Soleus Capital Management L.P. increased its stake in shares of Krystal Biotech by 65.2% in the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock worth $56,144,000 after buying an additional 141,400 shares during the period. GAMMA Investing LLC raised its holdings in Krystal Biotech by 50,249.4% during the 1st quarter. GAMMA Investing LLC now owns 121,342 shares of the company's stock valued at $21,878,000 after buying an additional 121,101 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Krystal Biotech during the 4th quarter valued at $15,989,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after acquiring an additional 71,200 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.